Incidences of thromboembolic events (TEE) reported in various trials utilizing thalidomide plus alkylating agents.
| Regimen . | Disease Status . | TEE Prophylaxis . | TEE Incidence . | Reference . |
|---|---|---|---|---|
| *After addition of enoxaparin 40 mg daily, incidence decreased to 3%, resulting in overall incidence of 12% for patients receiving MP + thalidomide on this study. | ||||
| Abbreviations: CTX, cyclophosphamide; DEX, dexamethasone; MEL, melphalan; MP, melphalan + prednisone; NDMM, newly diagnosed multiple myeloma; NR, not reported; PD, progressive disease; PRED, prednisone; RRMM, relapsed/refractory multiple myeloma; THAL, thalidomide | ||||
| MEL 8 mg/m2 d 1–4 DEX 12 mg/m2 d 1–4, 17–20 THAL 300 mg d 1–4, 17–20 | NDMM | None | 10% | Dimopoulos et al24 |
| MEL 4 mg/m2 d 1–7 PRED 40 mg/m2 d 1–7 THAL 100 mg/day (until PD) | NDMM | None* | 20%* | Palumbo et al25 |
| MEL 0.25 mg/kg d 1–4 PRED 2 mg/kg d 1–4 THAL ≤ 400 mg/d (until end of MP) | NDMM | None | 12% | Facon et al2 |
| CTX 500 mg P.O. d 1,8,15 DEX 40 mg d 1–4, 15–18 THAL 100–200 mg/day | NDMM (15) RRMM (46) | None | 3% | Williams et al26 |
| CTX 300 mg/m2 q wk DEX 40 mg/d × 4 d q mo. THAL ≤ 300 mg/day | RRMM | Warfarin 1 mg/day | 11.5% | Kyriakou et al27 |
| CTX 50 mg/day DEX 40 mg/d × 4 d q 3 wks THAL 200–800 mg/d | RRMM | None | 7% | Garcia-Sanz et al28 |
| CTX 150 mg/m2 P.O. q 12 hr × 5 d DEX 20 mg/m2 d 1–4, 15–18 THAL 400 mg/day d 1–5, 14–18 | RRMM | None | 4% | Dimopoulos et al29 |
| CTX 100–150 mg/day THAL 100–400 mg/day | RRMM | None | 3% | Hovenga et al30 |
| CTX 300 mg/m2 q 12 hrs × 6 DEX 20 mg/m2 d 1–4, 9–12, 17–20 THAL 100–400 mg/day | RRMM | None | 9% | Kropff et al31 |
| CTX 400 mg/m2 CIV d 1–4 VP-16 40 mg/m2 CIV d 1–4 DEX 40 mg/day d 1–4 q 28 d | RRMM | NR | NR | Moehler et al32 |
| Regimen . | Disease Status . | TEE Prophylaxis . | TEE Incidence . | Reference . |
|---|---|---|---|---|
| *After addition of enoxaparin 40 mg daily, incidence decreased to 3%, resulting in overall incidence of 12% for patients receiving MP + thalidomide on this study. | ||||
| Abbreviations: CTX, cyclophosphamide; DEX, dexamethasone; MEL, melphalan; MP, melphalan + prednisone; NDMM, newly diagnosed multiple myeloma; NR, not reported; PD, progressive disease; PRED, prednisone; RRMM, relapsed/refractory multiple myeloma; THAL, thalidomide | ||||
| MEL 8 mg/m2 d 1–4 DEX 12 mg/m2 d 1–4, 17–20 THAL 300 mg d 1–4, 17–20 | NDMM | None | 10% | Dimopoulos et al24 |
| MEL 4 mg/m2 d 1–7 PRED 40 mg/m2 d 1–7 THAL 100 mg/day (until PD) | NDMM | None* | 20%* | Palumbo et al25 |
| MEL 0.25 mg/kg d 1–4 PRED 2 mg/kg d 1–4 THAL ≤ 400 mg/d (until end of MP) | NDMM | None | 12% | Facon et al2 |
| CTX 500 mg P.O. d 1,8,15 DEX 40 mg d 1–4, 15–18 THAL 100–200 mg/day | NDMM (15) RRMM (46) | None | 3% | Williams et al26 |
| CTX 300 mg/m2 q wk DEX 40 mg/d × 4 d q mo. THAL ≤ 300 mg/day | RRMM | Warfarin 1 mg/day | 11.5% | Kyriakou et al27 |
| CTX 50 mg/day DEX 40 mg/d × 4 d q 3 wks THAL 200–800 mg/d | RRMM | None | 7% | Garcia-Sanz et al28 |
| CTX 150 mg/m2 P.O. q 12 hr × 5 d DEX 20 mg/m2 d 1–4, 15–18 THAL 400 mg/day d 1–5, 14–18 | RRMM | None | 4% | Dimopoulos et al29 |
| CTX 100–150 mg/day THAL 100–400 mg/day | RRMM | None | 3% | Hovenga et al30 |
| CTX 300 mg/m2 q 12 hrs × 6 DEX 20 mg/m2 d 1–4, 9–12, 17–20 THAL 100–400 mg/day | RRMM | None | 9% | Kropff et al31 |
| CTX 400 mg/m2 CIV d 1–4 VP-16 40 mg/m2 CIV d 1–4 DEX 40 mg/day d 1–4 q 28 d | RRMM | NR | NR | Moehler et al32 |